STF-62247

Catalog No.S1041

STF-62247 shows selectivtoxicity and growth inhibition of renal cells lacking VHL; 25-fold greater sensitivity observed for cells with VHL deficiency compared to wild-type (VHL+).

Price Stock Quantity  
In DMSO USD 90 In stock
USD 70 In stock
USD 170 In stock
USD 270 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

STF-62247 Chemical Structure

STF-62247 Chemical Structure
Molecular Weight: 267.35

Validation & Quality Control

Quality Control & MSDS

Related Compound Libraries

STF-62247 is available in the following compound libraries:

Product Information

  • Compare Others
    Compare Others

Product Description

Biological Activity

Description STF-62247 shows selectivtoxicity and growth inhibition of renal cells lacking VHL; 25-fold greater sensitivity observed for cells with VHL deficiency compared to wild-type (VHL+).
Targets
IC50
In vitro In vitro, STF-62247 shows cytotoxicity and tumor growth inhibitory activity against wild-type VHL and VHL-deficient renal cell carcinoma (RCC) in a HIF-independent manner with IC50 of 16 μM and 0.625 μM, respectively. Moreover, STF-62247 also leads to cell death by increasing acidification and inducing autophagy in VHL-deficient cells. [1] STF-62247 specifically induces macroautophagy and enhances the fusion of autophagosome and lysosomes to form autolysosomes by interfering with Golgi-endoplasmic reticulum transport in cells that have lost VHL . [2] A recent study shows that induction of autophagy by STF-62247 increases sensitivity of RCC under hypoxic conditions to radiation in a VHL-dependent manner. [3]
In vivo In vivo mouse model, STF-62247 at a dose of 8 mg/kg byby intraperitoneal injection significantly reduces tumor growth of VHL-deficient SN12C tumor cells. [1]
Features

Protocol(Only for Reference)

Cell Assay: [1]

Cell lines SN12C and RCC4
Concentrations 0 to 40 μM
Incubation Time 24 hours
Method For cell viability, 100,000 cells are plated in a 12-well plate. The following day, 1.25 μM STF-62247 is added in the presence or absence of 1 mM 3-MA for 24 hours at 37 °C. Cells are trypsinized and counted by trypan blue exclusion. For XTT assays, 5000 RCC4 with and without VHL cells or 2,500 SN12C with and without VHL shRNA cells are plated in 96-well plates. The following day, vehicle (DMSO), STF-62247 is added to media by serial dilution. Four days later, the media is aspirated and XTT solution containing 0.3 mg/ml of XTT in Phenol Red-free media, 20% FCS and 2.65 mg/ml N-methyl dibenzopyrazine methyl sulfate (PMS) is added to the cells and incubated at 37 °C for 1-2 hours. Metabolism of XTT is quantified by measuring the absorbance at 450 nm on a plate reader.

Animal Study: [1]

Animal Models SN12C, SN12C-VHL shRNA or 786-O cells are injected subcutaneously into the flanks of immune-deficient mice.
Dosages ≤8 mg/kg
Administration Administered via i.p.
Solubility 1% DMSO/30% polyethylene glycol/1% Tween 80, 7 mg/mL
1

References

Clinical Trial Information( data from http://clinicaltrials.gov)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT01829321 Recruiting Ulcerative Colitis Galapagos NV 2013-04 Phase 2
NCT01852305 Recruiting Obstructive Sleep Apnea University Health Network, Toronto|St. Michael's Hospital, Toronto|Toronto East General Hospital 2013-04
NCT01609842 Not yet recruiting Cardiovascular Disease|Acute Coronary Syndrome Department of Veterans Affairs 2013-04
NCT01779466 Recruiting Nocturia Ferring Pharmaceuticals 2013-04 Phase 2
NCT01829061 Not yet recruiting Diabetes Quotient Diagnostics Limited 2013-04

Chemical Information

Download STF-62247 SDF
Molecular Weight (MW) 267.35
Formula

C15H13N3S

CAS No. 315702-99-9
Storage 3 years -20℃Powder
6 months-80℃in DMSO
Syonnyms N/A
Solubility (25°C) * In vitro DMSO 53 mg/mL (198 mM)
Water <1 mg/mL (<1 mM)
Ethanol 3 mg/mL (11 mM)
In vivo 1% DMSO/30% polyethylene glycol/1% Tween 80, 7 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name 4-(pyridin-4-yl)-N-m-tolylthiazol-2-amine

Preparing Stock Solutions

Stock Solution (1ml DMSO) 1mM 10mM 20mM 30mM
Mass(mg) 0.26735 2.6735 5.347 8.0205

Research Area

Tech Support & FAQs

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related Others

  • SRPIN340

    SRPIN340 is a selective SRPK inhibitor with Ki of 0.89 μM for SRPK1, showing no significant inhibitory activity against more than 140 other kinases..

    Features:The only specific SRPK1 and SRPK2 inhibitor. Potential use in congenital diseases and viral diseases including HIV, HCV and HBV.

  • AZ191

    AZ191 is a potent and selective DYRK1B inhibitor with IC50 of 17 nM, about 5- and 110-fold selectivity over DYRK1A and DYRK2, respectively.

  • RI-1

    RI-1 is a RAD51 inhibitor with IC50 ranging from 5 to 30 μM.

    Features:A selective recombinant RAD51 protein inhibitor discovered in 2012. Valuable tool for mechanistic studies of DNA repair and potential for use in many cancers.

  • CX-4945 (Silmitasertib)

    CX-4945 is a potent and selective inhibitor of CK2 (casein kinase 2) with IC50 of 1 nM, less potent to Flt3, Pim1 and CDK1 (inactive in cell-based assay). Phase 1.

    Features:First clinical inhibitor of CK2.

  • Tacrolimus (FK506)

    FK-506 is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • Bendamustine HCl

    Bendamustine HCL is a DNA-damaging agent with IC50 of 50 μM.

  • Posaconazole

    Posaconazole is a sterol C14ɑ demethylase inhibitor with an IC50 of 0.25 nM.

    Features:Currently the most advanced candidate for the treatment of Chagas disease.

  • Cidofovir

    Cidofovir suppresses virus replication by selective inhibition of viral DNA synthesis.

  • Simvastatin

    Simvastatin is a competitive inhibitor of HMG-CoA reductase with Ki of 0.1-0.2 nM .

  • Streptozotocin (STZ)

    Streptozotocin is a glucosamine-nitrosourea derivative, which is a methylating, carcinogenic, antibiotic and diabetes inducing agent.

Recently Viewed Items

Tags: buy STF-62247 | STF-62247 supplier | purchase STF-62247 | STF-62247 cost | STF-62247 manufacturer | order STF-62247 | STF-62247 distributor
Contact Us